Geneva, June 22 -- International Clinical Trials Registry received information related to the study (ChiCTR2600126576) titled 'A Study of Iparomlimab and Tuvonralimab as Neoadjuvant Therapy Before Concurrent Chemoradiotherapy and Maintenance Therapy After Concurrent Chemoradiotherapy in Advanced Cervical Cancer' on June 11.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Hubei Cancer Hospital

Condition: uterine cervical cancer

Recruitment Status: Not Recruiting

Phase: 4

Date of First Enrollment: 2026-06-16

Target Sample Size: Experimental group:45;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=326324

Disclaimer: Curated by HT Syndication....